New gout combo drug enters early human testing
NCT ID NCT07367971
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study is testing whether a new investigational drug called ABP-671 can be safely taken together with the standard gout medication allopurinol. Twenty adults with gout who are already on a stable dose of allopurinol will take the drugs alone and together over three weeks. The main goal is to measure how the two drugs interact in the body, not yet to see if ABP-671 improves gout symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABP-671 (an investigational drug) and allopurinol (a standard gout medication)
What this could lead to
If successful, this study could show that ABP-671 can be safely added to allopurinol therapy, potentially offering a new combination option for controlling gout.
What could go wrong
This is a very early Phase 1 study with only 20 participants. It is designed to check drug interactions, not to prove that ABP-671 works for gout. The results may not lead to a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GOUT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wakefield Clinical Research
RECRUITINGCary, North Carolina, 27560, United States
Contact